Pulmonary Drug Delivery Systems Market Share and Growth Analysis: Forecast and Key Trends

Cloud PRWire

The global pulmonary drug delivery systems market, valued at approximately US$50 billion in 2021, is poised for robust growth in the coming years, according to a comprehensive market analysis. This report sheds light on key trends and regional insights, providing a clear overview of the market landscape.

Pulmonary Drug Delivery Systems: A Non-Invasive Medical Breakthrough

Pulmonary drug delivery systems have gained prominence due to their non-invasive approach, enabling medications to be inhaled directly into the lungs and swiftly enter the bloodstream through the alveolar epithelium. This method is a vital alternative to subcutaneous and intravenous injections, enhancing drug efficacy. Devices such as nebulizers, metered-dose inhalers, and dry powder inhalers play a pivotal role in respiratory drug delivery, particularly for protein and peptide drugs. These systems are instrumental in treating respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD), reducing systemic side effects and increasing drug bioavailability.

Key Report Findings

  • Global pulmonary drug delivery systems market revenue reached approximately US$50 billion in 2021.
  • Rising prevalence of chronic diseases, particularly COPD, is a major growth driver.
  • Greater efficacy and precision in drug delivery are expected to fuel market growth.
  • North America is set to dominate the market during the forecast period.
  • Leading market participants include Philips Respironics, GlaxoSmithKline PLC, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., and 3M Healthcare.

Driving Growth Factors

  1. Rising Prevalence of COPD The surge in chronic obstructive pulmonary disease (COPD) cases has boosted the pulmonary drug delivery systems market. Delivering drugs directly to the disease site offers rapid relief with fewer systemic side effects, making this method highly desirable for patients.
  2. Growing Activism Around Pulmonary Drug Delivery Devices Awareness campaigns advocating the use of pulmonary drug delivery devices have gained traction, creating opportunities for market players. Governments worldwide are promoting these devices, and the development of smart inhalers for asthma and COPD patients further drives growth.

Challenges

  1. Lack of Training and Understanding While awareness of pulmonary drug delivery systems benefits is increasing, individuals often lack training and understanding of these techniques and devices, hindering market growth.
  2. Regulatory Concerns and Pricing Pressures Stringent regulatory processes may restrict market growth, and pricing pressures could negatively impact affordability.

Key Segments

  • Products Segment: Metered dose inhalers (MDIs) dominate, with novel MDI developments offering lucrative opportunities. Dry powder inhalers (DPIs) are cost-effective and require less preparation time.
  • Application Segment: Asthma is the most prominent application, driven by its increasing prevalence. COPD also sees substantial growth due to government initiatives.
  • Distribution Channel: Hospital pharmacies lead due to extensive treatments and quick reimbursements. Retail pharmacies and e-commerce show promising growth.
  • End-Use: Hospitals dominate with advanced medical devices. Home care is on the rise, driven by portable, small-sized devices.

Regional Outlook

North America is expected to experience exceptional growth, driven by the rising incidence of diseases like asthma and COPD, advanced healthcare infrastructure, and the presence of pharmaceutical and medical device players.

Leading Industry Participants

Key players in the global pulmonary drug delivery systems market include Philips Respironics, GlaxoSmithKline PLC, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., 3M Healthcare, PARI GmbH, F. Hoffmann-La Roche AG, Gilbert Technologies, AstraZeneca PLC, and Omron Healthcare, Inc.

Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2030 By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) https://www.fairfieldmarketresearch.com/report/pulmonary-drug-delivery-systems-market

Our Blogs:

https://ibusinessday.com/global-resin-furniture-market-on-the-verge-of-remarkable-growth-projected-to-surpass-us25-billion-by-2030/

http://www.pml4all.org/profiles/blogs/global-resin-furniture-market-poised-for-exceptional-growth

About Us

Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of

services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.

Contact

Fairfield Market Research

London, UK

UK +44 (0)20 30025888

USA (Toll-free) +1 (844) 3829746

Web: https://www.fairfieldmarketresearch.com/

Email: sales@fairfieldmarketresearch.com

LinkedIn | Twitter

This press release first seen on Brilad

comtex tracking

COMTEX_441947496/2840/2023-10-15T22:54:34